GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » EBITDA Margin %

Entheon Biomedical (XCNQ:ENBI) EBITDA Margin % : 0.00% (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Entheon Biomedical's EBITDA for the three months ended in Feb. 2024 was C$-0.08 Mil. Entheon Biomedical's Revenue for the three months ended in Feb. 2024 was C$0.00 Mil. Therefore, Entheon Biomedical's EBITDA margin for the quarter that ended in Feb. 2024 was 0.00%.


Entheon Biomedical EBITDA Margin % Historical Data

The historical data trend for Entheon Biomedical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical EBITDA Margin % Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
EBITDA Margin %
Get a 7-Day Free Trial - - - -1,893.68 -125.60

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.83 -23.85 - - -

Competitive Comparison of Entheon Biomedical's EBITDA Margin %

For the Biotechnology subindustry, Entheon Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's EBITDA Margin % falls into.



Entheon Biomedical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Entheon Biomedical's EBITDA Margin % for the fiscal year that ended in Nov. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Nov. 2023 )/Revenue (A: Nov. 2023 )
=-0.314/0.25
=-125.60 %

Entheon Biomedical's EBITDA Margin % for the quarter that ended in Feb. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2024 )/Revenue (Q: Feb. 2024 )
=-0.078/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Entheon Biomedical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines